

NOVAVAX INC
Form 8-K
May 05, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT PURSUANT TO 13 or 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 5, 2004

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

0-26770

(Commission
File No.)

22-2816046

(I.R.S. Employer
Identification No.)

8320 Guilford Road, Columbia, MD

(Address of principal executive offices)

21046

(Zip code)

(301) 854-3900

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

**NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT**

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

99.1 Press Release dated May 5, 2004.

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On May 5, 2004, Novavax, Inc. reported its first quarter earnings for 2004.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 5, 2004 By: NOVAVAX, INC.
/s/ Dennis W. Genge
Dennis W. Genge
Vice President and Chief Financial Officer